Background: The purpose of the study was to assess the safety, tolerability, recommended phase II dose (RPTD), and preliminary antitumor activity of the combination of carboplatin-paclitaxel (Taxol)-temsirolimus. Materials and methods: Patients with solid malignancies suitable for carboplatin-paclitaxel (CP) chemotherapy and two or less prior lines of chemotherapy received 15, 20, or 25 mg of temsirolimus per week with CP given every 21 days. Thirty-eight eligible patients were entered into six dose levels with the first two levels administering temsirolimus on days 8 and 15 and the subsequent four dose levels switching to days 1 and 8 temsirolimus administration.
introduction
The mammalian target of rapamycin (mTOR) is a multifunctional serine-threonine kinase that acts as a central regulator of cell growth, proliferation, and apoptosis [1, 2] . Inhibition of mTOR activity in vitro blocks tumor growth and thus mTOR has become an interesting target for anticancer strategies with several mTOR inhibitors being in clinical development [3, 4] . Everolimus and temsirolimus have been approved for the treatment of kidney cancer. Increasing evidence from phase II studies suggests that temsirolimus has significant single-agent activity in a variety of other tumor types [5] [6] [7] [8] [9] . Temsirolimus is well tolerated with mild predominantly mucocutaneous toxicity (i.e. mucositis, rash, and diarrhea). Grade 3 toxic effects have been reported rarely and include neutropenia, thrombocytopenia, hyperglycemia, and hyperlipidemia.
There is a strong rationale for combining temsirolimus with cytotoxic chemotherapy. Preclinical studies in cell lines and tumor models suggest synergy between temsirolimus and different chemotherapy agents including doxorubicin, gemcitabine, cisplatin, and taxanes [10, 11] . The combination of temsirolimus and cisplatin was more active than either agent alone in breast cancer, head-neck cancer, and melanoma cell lines. The addition of temsirolimus to cisplatin also appeared to reverse cisplatin resistance in lung cancer cell lines [12] . In preclinical studies, inhibition of the mTOR pathway by temsirolimus inhibited repopulation of prostate cancer cell lines between courses of taxane-based chemotherapy [13] . Thus, combining chemotherapy with an mTOR inhibitor characterized by a different mechanism of action and nonoverlapping toxicity represents an attractive hypothesis that may translate into enhanced clinical activity for different tumor types including gynecological malignancies.
The combination of carboplatin-paclitaxel (CP) is a widely used standard regimen in the treatment of patients with gynecologic, non-small-cell lung, primary unknown, and other cancers [14] [15] [16] [17] [18] . CP is generally well tolerated with myelosuppression, nausea-vomiting, neurotoxicity, and alopecia as the most common toxic effects [19] .
The NCIC-Clinical Trials Group (CTG) recently completed a phase II study of temsirolimus given weekly at a dose of 25 mg in patients with advanced/metastatic endometrial cancer [5] . A promising partial response (PR) and stable disease rate of 83% in chemotherapy-naive and 52% in chemotherapytreated patients was observed.
Based on these preclinical and clinical observations and the lack of significant overlapping toxicity, the current phase I study attempted to establish the maximum tolerated dose (MTD) and recommended phase II dose (RPTD) of weekly temsirolimus in combination with CP and seek preliminary evidence of antitumor activity in patients with advanced solid cancers.
materials and methods

patient population
Eligibility criteria for admission to the study included the following: histologically confirmed solid tumor not curable by standard therapies, for which treatment with CP was a reasonable therapeutic option; age ‡18 years; written informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of one or less; two or less prior chemotherapy regimens; absolute granulocytes ‡1.5 · 10 9 /l, platelets ‡100 · 10 9 /l, bilirubin <1.5 · upper normal limit (UNL), alanine aminotransferase/ aspartate aminotransferase (AST) <3 · UNL (<5 · UNL if liver metastases present); creatinine clearance >50 ml/min (Cockcroft-Gault formula).
study objectives
Primary objectives of the study were to assess the safety and tolerability of temsirolimus when combined with CP administered on day 1 of a 3-week cycle and to establish its MTD and RPTD in patients with advanced solid malignancies. Secondary objectives were to describe the frequency and severity of toxic effects of this combination given at the recommended dose and schedule as well as to explore antitumor activity.
study design
This was a multicenter, open-label phase I trial of temsirolimus in combination with standard CP chemotherapy in patients with advanced solid tumors carried out by the NCIC-CTG. Patients were recruited at three Canadian centers. Temsirolimus was provided by the Cancer Therapy Evaluation Program, National Cancer Institute, United States. Commercial supply of paclitaxel and carboplatin was used.
The starting dose of temsirolimus was 25 mg i.v. given on days 8 and 15, which represented two-thirds of the normal total 3-weekly temsirolimus dose. The starting dose of carboplatin was area under the curve (AUC) 5 mg/ml/min and of paclitaxel was 135 mg/m 2 over 3 h, both given on day 1.
These doses were considered within the active therapeutic range for both drugs and are doses used in standard care. Day 1 temsirolimus was omitted due to concerns of additive toxicity, which was seen when temsirolimus was given together with chemotherapy on the same day in previously reported trials [20] . Treatment was given in 21-day cycles.
Although it was initially planned to escalate doses of CP to a maximum dose of carboplatin AUC 6 mg/ml/min, paclitaxel 175 mg/m 2 on day 1, and temsirolimus 25 mg on days 8 and 15, it was determined from the initial dose expansion cohorts that this would not be feasible because nadir counts on day 15 were substantially limiting temsirolimus delivery on that day. Therefore, escalation was abandoned for part A at the second dose level and a revision to part B made with temsirolimus given on days 1 and 8 ( Table 1) . Dose escalation followed a standard 3 + 3 design (three to six patients per cohort).
Dose escalation to the next dose level occurred if none of the three patients at the current dose level exhibited a dose-limiting toxicity (DLT). If one patient exhibited a DLT at any dose level, then a maximum of three additional patients were accrued and treated at that dose level. If less than two of six patients experienced a DLT, accrual started at the next higher dose level. Each dose level could be further expanded by three to four patients if the NCIC-CTG and investigators agreed that more experience was required at that level and MTD had not been declared. If two or more of six patients experienced a DLT on a dose level, then that dose was to be declared the MTD. The next lower dose was to be the RPTD. There was a planned expansion at the RPTD level for endometrial and ovarian cancer patients.
Patients experiencing DLTs had their treatment interrupted until recovery to grade 1 or less toxicity and/or had a dose reduction by one dose level. There was no intrapatient dose escalation. Up to eight cycles of treatment were planned in the absence of disease progression or unacceptable toxicity. In selected cases, treatment was continued beyond eight cycles if there was evidence of ongoing benefit.
Toxicity was graded according to National Cancer Institute-Common Toxicity Criteria (NCI-CTC) version Common Terminology Criteria for Adverse Events-V3.0. A DLT was defined as any of the following occurring in cycle 1: NCI-CTC grade 3/4 non-hematological toxicity (excluding 
Annals of Oncology original articles
nausea/vomiting, unless optimal antiemetic treatment was given); grade 4 thrombocytopenia or thrombocytopenic bleeding; grade 4 uncomplicated neutropenia ‡7 days; febrile neutropenia or ‡grade 3 infection with grade 3/ 4 neutropenia; treatment delay >2 weeks due to any toxicity; other toxic effects of concern to the NCIC-CTG; missing or reducing two doses of temsirolimus. Asymptomatic laboratory abnormalities where supportive management was feasible (e.g. hypophosphatemia) were not considered DLTs.
All patients provided written informed consent. The study was approved by the local ethics committees of all participating centers.
safety assessments
Adverse events (AEs) were recorded for 28 days after the last dose of study drug and defined as any undesirable symptom or medical condition occurring after starting study treatment regardless of whether it was treatment related. Serious AEs were recorded throughout the study and up to 4 weeks after the end of therapy and were defined as any AE that was fatal or life-threatening, required prolonged hospitalization, resulted in persistent or significant disability/incapacity, or required medical or surgical intervention.
response assessments
Disease was evaluated at baseline using physical examination and computed tomography (CT) scans and reassessed every two cycles. Response was assessed by RECIST [21] . All patients with measurable disease at baseline as defined by RECIST who had received at least one cycle of therapy and had their disease reevaluated were considered assessable for response.
statistical methods
Descriptive statistics were used to summarize demographic and baseline disease characteristics. The safety population included all patients who received at least one dose of study medication. Data analysis was carried out using SAS software (Version 9.1.3; SAS Institute Inc. Toronto, Ontario, Canada).
results
patient characteristics
Thirty-nine patients were registered for the trial. One patient was withdrawn due to hospitalization for progressive disease before treatment start. Thirty-eight patients, 82% being female, were enrolled and treated in a total of six dose cohorts. One patient was ineligible (three prior chemotherapy regimens) but included in the toxicity analysis. Table 2 summarizes the patient characteristics. Approximately half of the patients had gynecological tumors. The median age was 59 years (range 30-79) and the median ECOG performance status was one. Thirteen patients were chemonaive, while the remaining patients were pretreated.
drug delivery
A total of 235 cycles of CP plus temsirolimus were administered. Dose delays occurred in some cycles at all dose levels, mainly due to hematological toxicity and patient request. Dose reductions for temsirolimus were required in almost all patients on day 15 of the 3-week cycle on dose levels 1 and 2 due to hematological toxicity that prompted the change to administer temsirolimus on days 1 and 8 of the 3-week cycle. Dose intensity is shown in Table 3 . Deliverability of temsirolimus in particular improved substantially after 
toxicity, DLT and MTD
AEs were generally mild or moderate and largely consistent with the known side-effect profile of CP alone. One DLT was observed in the first five dose levels. On dose level 2, one patient developed grade 3 infection with grade 3 neutropenia and fever. On dose level 6, three DLTs were documented: two patients with grade 4 thrombocytopenia and one patient with grade 3 fatigue combined with several other grade 2 toxic effects (Table 3) . Hence, dose level 6 was declared the MTD and dose level 5 with carboplatin at AUC 5 mg/ml/ min and paclitaxel at 175 mg/m 2 both given on day 1 plus temsirolimus at 25 mg given on days 1 and 8 was the RPTD.
Thirty-eight patients were assessable for hematological toxicity (Table 4) . Grade 3/4 neutropenia was observed in 34 patients (89%) but was mostly not associated with significant complications. Four patients had significant infections. Three patients developed neutropenic fever or neutropenic infections and in one patient, reactivation of a preexisting hepatitis B occurred. Despite the immunosuppressive potential of temsirolimus and the substantial leukocytopenia, no other opportunistic infections developed. Although 33 patients developed thrombocytopenia, it was <grade 3 in all but eight.
All thirty-eight patients were also assessable for nonhematological toxicity (Table 5) . Overall, severe nonhematological toxicity grade 3/4 was <5% with three grade 4 events documented, one patient with severe fatigue, one with severe back/muscle pain, and one with deep vein thrombosis.The latter two patients' grade 4 toxic effects were deemed treatment unrelated by the investigators since the back pain predated treatment and the thrombosis coincided with rapid and massive tumor progression. The most common nonhematological AEs thought to be at least possibly related to protocol therapy include fatigue, rash, mucositis, nausea/ vomiting, diarrhea, alopecia, nosebleeds, muscle pain, and neuropathy. Although 63% of patients developed treatmentrelated neuropathy, only two patients had grade 3 neuropathy and none grade 4. Similarly, 68% of patients developed any grade of functional/symptomatic mucositis and another 13% had clinically visible mucositis but only one patient was observed with grade 3 mucositis. Two patients developed temsirolimus-related pneumonitis, grades 1 and 3, respectively.
In patients with normal baseline chemistry, elevation of cholesterol, glucose, and phosphate has been seen. Grade 3 aberrations were documented on dose level 2 (AST, hypokalemia, hyperglycemia, and hypophosphatemia), on dose level 5 [hyperglycemia, hypokalemia, and hypophosphatemia (2)], and on dose level 6 (hypophosphatemia (2), hypokalemia, hyperglycemia, and hypertriglyceridemia). Biochemical toxicity led to treatment modification in three patients. 
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All patients have gone off study. Nine subjects had objective progressive disease, one non-RECIST progression and two symptomatic progressions. Ten patients stopped for AEs, which included grade 3 sensory neuropathy (two patients), grade 3 infection (two patients), and one patient each with grade 3 febrile neutropenia, grade 2 sensory neuropathy, prolonged grade 2 neutropenia, grade 1 allergic reaction, grade 3 fatigue, and grade 2 viral hepatitis. Fourteen patients completed treatment, one refused treatment and one was removed due to the decision of the investigator.
responses
Response was evaluable in the 37 eligible patients, all of whom had measurable disease. The overall response rate was 46% (95% confidence interval 29.5% to 63.1%). No complete responses but 17 PRs were observed with a median duration of 7.4 months (range 2.8-19.4 months). Eighteen patients (49%) had stable disease lasting from 1.3 to 18.1 months with a median duration of 7.6 months. Two patients had a best response of progression. Within the group of 11 endometrial cancer patients (all treated on part B with days 1 and 8 temsirolimus), 9 (82%) responses were observed and of the --30  79  68  Sensory neuropathy  2  -30  79  63  Nausea  1  -26  68  61  Muscle pain  2  1  29  76  55  Rash  --21  55  53  Vomiting  3  -18  47  45  Nosebleeds  --17  45  42  Joint pain  3  -16  42  37  Diarrhea  3  -15  39  34  Headaches  --14  37  32  Taste changes  --11  29  24  Constipation  1  -25  66  24  Edema  1  -17  45  21  Anorexia  --13  34  21  Flushing  --7  18  18  Allergic reaction  1  -8  21  18  Pruritus  --9  24  18  Heartburn  1  -15  39  16  Cough  --18  47  16  Abdominal pain  --19  50  16  Rhinitis  --8  21  16  Acne  --6  16  16  Insomnia  --15  39  11  Rigors/chills  --12  32  11  Muscle weakness  1  -5  13  11  Bruising  --7  18  11  Nail changes  --4  11  11  Dyspnea  --14  37  11  Neutropenic infection or febrile neutropenia  3  -3  8  8  Dry mouth  --7  18  8  Dizziness  --5  13  8  Fever  --8  21  8  Injection site reaction  --4  11  5  Dysphagia  --5  13  5  Back pain  -1  11  29  3 original articles Annals of Oncology 6 ovarian cancer patients, 3 had a PR and 3 had stable disease (1 ovarian patient with a PR to study therapy was found to be ineligible because of three prior chemotherapy regimens) (Figure 1) . Five of the six ovarian cancer patients and two of the endometrial cancer patients had previously been treated with one chemotherapy regimen.
discussion
This phase I study demonstrates that the combination of CP plus temsirolimus is feasible with an RPTD of carboplatin AUC 5 mg/ml/min given on day 1, paclitaxel 175 mg/m 2 given on day 1 and temsirolimus 25 mg administered on days 1 and 8 every 3 weeks. Myelotoxicity, in particular granulocytopenia and thrombocytopenia, and fatigue were the main DLTs of this regimen and prompted the change in the schedule of administration of temsirolimus from days 8 and 15 to days 1 and 8.Our data demonstrate that days 1 and 8 temsirolimus application was more feasible than days 8 and 15 schedule, which was contrary to the expectations of excessive toxicity based on previously published studies. Day 15 administration was not feasible as this corresponded to the nadir induced by chemotherapy. At the recommended dose level, the dose intensity of temsirolimus was 56% of that planned due to the days 1 and 8 schedule, whereas the dose intensities of carboplatin and paclitaxel were >80% of that planned. This is not surprising given overlapping myelosuppression of the agents and the difficulty of administering temsirolimus on a weekly schedule in face of myelosuppression from day 1 chemotherapy dosing. Our strategy was to obtain a combination of these agents that maintained the doses of carboplatin and paclitaxel close to those used as single agents. An alternate development strategy would have been to attempt to deliver a higher dose intensity of temsirolimus but this would have been at the expense of carboplatin and paclitaxel dosing, and this would have been a more challenging regimen to move into future randomized trials.
Although grade 3 or 4 neutropenia occurred in the majority of patients (89%) and at all dose levels on this trial, it was of short duration and manageable. Only one patient developed febrile neutropenia and two had grade 3 infection with grade 3 or 4 neutropenia documented over the course of the study. All were successfully managed with i.v. and/or oral antibiotics plus supportive measures. Thrombocytopenia was seen in our patients but without clinically significant bleeding or need for platelet transfusion. Although a DLT of temsirolimus at very high doses, grade 3/4 thrombocytopenia is rarely observed with the 25-mg weekly schedule [22, 23] . Myelotoxicity rates similar to the rates observed in our phase I study have been reported with the combination of CP alone within large randomized studies [16, 24] .
Opportunistic infections are of concern with temsirolimuscontaining combinations due to potential immunosuppression. An increased risk for these infections was observed for the combination of temozolomide and temsirolimus in patients with malignant gliomas [25] . Despite the additional significant myelotoxicity of our regimen, no episodes of opportunistic infections were observed in this study. One patient developed reactivation of preexisting hepatitis B, a phenomenon that has been described with both chemotherapy alone as well as mTOR inhibition [26, 27] .
Non-hematological toxicity was generally mild to moderate with only few grade 3/4 toxic effects and consistent with the side-effect profile reported in the literature for CP and for temsirolimus as a single agent. Neurotoxicity rate was similar to other CP trials and did not appear to be increased with the addition to temsirolimus.
Overlapping toxic effects between chemotherapy agents and targeted therapies represent a particular problem. In a phase I trial, temsirolimus in combination with 5-fluorouracil was associated with unacceptable stomatitis as the predominant DLT seen at all dose levels with a total incidence of 89% [20] . This experience highlights the need for careful dose escalation when combining chemotherapy with a novel targeted agent and the careful selection of combinations with little or no overlapping toxic effects.
In our study, overlapping toxic effects of CP and temsirolimus such as fatigue, skin rash, diarrhea, vomiting, and mucositis/stomatitis occurred within the expected frequencies based on the existing data from previous trials and without a relevant increase in the number of grade 3/4 cases indicating that there was little or no additive toxicity. The majority of cases were managed with symptom-oriented supportive therapy rather than dose reductions or delays.
Only two cases of temsirolimus-related pneumonitis were observed despite ongoing surveillance including chest CT scans. Due to this low incidence of pneumonitis, frequent routine chest CT scanning does not seem necessary and should be limited to patients with dyspnea or other emergent symptoms such as dry cough or shortness of breath. Temsirolimus-associated hyperglycemia and hypertriglyceridemia did not appear to be more frequent or more severe in the current regimen as compared with temsirolimus as a single agent [22] .
Responses were seen with various tumor types. An overall objective response rate in all 37 eligible patients of 46% is Figure 1 . Antitumor activity of CP plus temsirolimus (n = 37). *Includes the one ovarian cancer patient with a PR to study treatment who was deemed to be ineligible because of three prior chemotherapy regimens. Four of the remaining five ovarian cancer patients had received one prior chemotherapy regimen. $ Two of the 11 patients with endometrial carcinoma had received one prior chemotherapy regimen. CP, carboplatin-paclitaxel; PR, partial response.
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encouraging. In addition, 49% patients had stable disease or minor responses and primary progression was very rare. The high response rate seen in endometrial and ovarian cancer patients warrants further development and is currently one of the arms of a Gynecologic Oncology Group randomized phase II clinical trial.
This study is one of the first reports of clinical experience with the novel combination of CP and temsirolimus. At dose levels studied, this combination was associated with acceptable and manageable toxicity. Based on the toxicity and response rates observed in this study, day 1 CP plus temsirolimus administered on days 1 and 8 every 3 weeks represents an active combination that requires further development. This study was designed to assess the tolerability and toxicity of this combination and did not assess maintenance therapy after completion of combination therapy or alternate CP schedules such as weekly application. These should be explored further in future clinical trials.
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